Real-world Effectiveness of Tofacitinib on Ulcerative Colitis Associated Spondyloarthropathy
- Sponsor
- Italian Group for the study of Inflammatory Bowel Disease (IG-IBD)
- Study ID
- NCT05431283
- Status
- Unknown
Conditions
- Spondyloarthropathy
- Ulcerative Colitis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Tofacitinib — DRUGThis study aims to assess the effectiveness of TOFA
Study Details
Tofacitinib (TOFA) is a JAK inhibitor already used in rheumatology for the treatment of moderate-to-severe active rheumatoid arthritis and psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease- modifying antirheumatic drugs. Furthermore, TOFA has been recently approved for the treatment of adult patients with moderate-to-severe active Ulcerative Colitis (UC) who had no response, lose response, or were intolerant to either conventional therapy or a biologic agent. The approval was based on the efficacy demonstrated by TOFA in three phase 3 randomized controlled trials named OCTAVE: two identically designed, 8-week, placebo- controlled, induction studies of oral TOFA 10 mg twice daily followed by the OCTAVE Sustain 52-week maintenance study. About sacroiliitis, 2 out of 8 patients treated with TOFA improved after 8 weeks, compared with 0 out of 3 patients in the placebo group. Obviously, these data should be interpreted with extreme caution since patient numbers were very low, and it should be again emphasized that these trials were not designed to explore the efficacy of TOFA onextraintestinal manifestations. On these premises, we designed a prospective, multicenter, observational, 52-week study with the aim of assess the effectiveness of TOFA on UC-associated spondyloarthropathy.
Key Dates
- Start date
- Apr 25, 2022
- Status verified
- Jun 2022
- Primary completion
- Dec 31, 2022
- Completion
- Dec 31, 2023
Study Design
- Enrollment
- 100 participants (estimated)
Primary Outcome Measure
joint response and steroid free joint response [ Time Frame: week 8 ]
Central Contacts
- Carola Lauritano+393397793868
Related Studies
- Immune Regulation in Ulcerative Colitis or Crohn s DiseaseRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
- Fecal Microbiome TransplantPHASE1 · Enrolling By Invitation · Judith Kelsen · Philadelphia, Pennsylvania
- Improving the Quality of Care for Adults With Inflammatory Bowel DiseaseEnrolling By Invitation · Dartmouth-Hitchcock Medical Center · Los Angeles, California
- The Influence of a Fasting Mimicking Diet on Ulcerative ColitisRecruiting · Stanford University · Palo Alto, California